CSIMarket
 
Avid Bioservices Inc   (CDMO)
Other Ticker:  
 
 
Price: $6.6000 $0.31 4.928%
Day's High: $6.7 Week Perf: 3.61 %
Day's Low: $ 6.18 30 Day Perf: -14.29 %
Volume (M): 1,901 52 Wk High: $ 21.05
Volume (M$): $ 12,547 52 Wk Avg: $11.02
Open: $6.29 52 Wk Low: $4.07



 Market Capitalization (Millions $) 417
 Shares Outstanding (Millions) 63
 Employees 326
 Revenues (TTM) (Millions $) 140
 Net Income (TTM) (Millions $) -11
 Cash Flow (TTM) (Millions $) -46
 Capital Exp. (TTM) (Millions $) 58

Avid Bioservices Inc
Avid Bioservices Inc is a biopharmaceutical company based in California. They specialize in providing contract manufacturing services for the development and production of biologics, such as monoclonal antibodies and recombinant proteins. Avid Bioservices has state-of-the-art facilities and a team of experienced professionals to support their clients' drug development programs. They have a strong track record of successfully delivering high-quality products to the biotechnology and pharmaceutical industries.


   Company Address: 14191 Myford Road Tustin 92780 CA
   Company Phone Number: 508-6100   Stock Exchange / Ticker: NASDAQ CDMO
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Financing Agreement

Avid Bioservices Announces Pricing of Private Placement of Convertible Notes.

Published Thu, Mar 7 2024 4:59 AM UTC

Avid Bioservices, Inc. (NASDAQ:CDMO), a renowned biologics contract development and manufacturing organization (CDMO), revealed the successful pricing of $160 million aggregate principal amount of 7.00% Convertible Senior Notes due 2029 (the 2029 Notes), as announced on March 6, 2024. In an effort to raise capital, the company entered into private placement purchase agreemen...

Shares

Avid Bioservices Inc. Announces $160 Million Convertible Notes Offering to Drive Growth and Value for Shareholders

Published Wed, Mar 6 2024 9:32 PM UTC

Convertible Senior Notes Offering by Avid Bioservices Inc. to Impact Shareholders and Financial Market
In a recent press release, Avid Bioservices Inc. (NASDAQ:CDMO) has revealed its plans to offer $160 million aggregate principal amount of Convertible Senior Notes due 2029 in a private placement to qualified institutional buyers. This move is expected to have a signific...

Avid Bioservices Inc

Financial Crisis Looms as Avid Bioservices Inc. Reports Plummeting Revenue in Fiscal Year Ending Oct 31, 2023



Avid Bioservices Inc has recently experienced a surge in its share price, gaining 11.96% over the past five trading days. However, the company's shares dropped significantly by -64.72% from the previous year and currently trade only 18.8% above its 52-week low. While these figures indicate a mix of positive and negative trends, it is essential to delve deeper into the company's financial results and interpret their implications for the future.
Recorded Second Quarter Revenue and New Business Orders:
Avid Bioservices Inc reported second-quarter revenue of $25.4 million. Although this represents a decline of -27.108% compared to the previous year's revenue of $34.76 million, it is crucial to note that the company managed to secure $35 million in new business orders during this period, resulting in a backlog of $199 million. This backlog indicates a robust pipeline of future revenue, which could potentially contribute to the company's growth.

Avid Bioservices Inc

Avid Bioservices Inc Falls Behind Peers Despite Gentle Revenue Growth of 1.112%

Avid Bioservices Inc, a contract development and manufacturing organization (CDMO), recently reported a loss per share of $-0.03 for the most recent fiscal period. This represents a decrease compared to earnings of $0.02 per share in the previous year and $0.00 per share in the prior financial reporting period. While the revenue experienced a gentle growth of 1.112% to $37.10 million from $36.69 million in the corresponding period a year prior, there was a sequential decrease of -6.782% from $39.80 million.
However, despite these numbers, Avid Bioservices Inc's business growth has fallen short in comparison to its peers in the Major Pharmaceutical Preparations industry. With an average growth of 2.98% recorded from the first quarter of 2023, Avid Bioservices Inc trails behind its competitors.

Avid Bioservices Inc

Despite a 27.455% Surge in Revenue, Avid Bioservices Inc's Q4 2023 Earnings Season Ends with Balanced Books

Avid Bioservices Inc, a major player in the pharmaceutical preparations industry, recently released its financial report for the quarter ending on April 30, 2023. While the company saw a surge in revenue, unfortunately, their profits did not follow suit. The report revealed that Avid Bioservices Inc's balances books reached a mere $0.00 per share, indicating that the company did not generate any profits.
However, despite the lackluster profit figures, it is worth noting that the revenue for the company experienced a significant growth of 27.455%, amounting to $39.80 million compared to the same quarter of the previous year, where revenue stood at $38.02 million, growing by 4.685%. This growth in revenue suggests that Avid Bioservices Inc is successfully attracting customers and generating sales.






 

Avid Bioservices Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com